FDA approvals, clinical trial results, insurance coverage changes, and breakthrough research in transcranial magnetic stimulation.
Our pick of the latest must-read TMS news.
BrainsWay says more than 70 million U.S. covered lives now sit under medical policies that cover its SWIFT accelerated Deep TMS protocol, up from 57 million in June. The release does not name the payers behind the latest additions.
Read full coverage →31 stories on FDA approvals, clinical trials, and emerging research.
BrainsWay says more than 70 million U.S. covered lives now sit under medical policies that cover its SWIFT accelerated Deep TMS protocol, up from 57 million in June. The release does not name the payers behind the latest additions.
Read more →Neuronetics said its TrakStar practice management platform now connects with the AdvancedMD EHR, which the company describes as the first TMS system integrated with an EHR/EMR. Availability begins in the fourth quarter for NeuroStar providers on AdvancedMD.
Read more →A small uncontrolled pilot in the Journal of Geriatric Psychiatry and Neurology reported that 10 of 12 patients with depression and early-stage Alzheimer's responded to a 36-session Deep TMS course. The findings are preliminary and Deep TMS is not FDA-cleared for Alzheimer's disease.
Read more →A secondary analysis in the Journal of Affective Disorders of 89 patients with major depression found the share with any suicidal ideation dropped from 22.5% to 6.7% after six weeks of Deep TMS. The analysis was not designed to test suicidality and has no sham comparison.
Read more →Nexstim reported first-half 2026 net sales of EUR 5.2 million, up 16.1%, and positive EBITDA for a fourth consecutive half-year. The report recaps the March 2026 FDA clearances of NBS 6 for adult OCD and adolescent depression.
Read more →BrainsWay reported second-quarter revenue of $17.1 million, up 35%, with a record 125 Deep TMS systems shipped. The company raised full-year 2026 revenue guidance to $68-70 million.
Read more →Neuronetics reported second-quarter revenue of $41.6 million, up 9.1%, with Greenbrook clinic revenue up 16.8% and NeuroStar revenue down 2.7%. Adjusted EBITDA turned positive at $0.3 million.
Read more →Greenbrook opened its largest center to date, a nearly 7,000-square-foot site in Rockville, Maryland offering NeuroStar TMS and Spravato. It will also serve as a clinical innovation and research hub for the network.
Read more →BrainsWay invested $3 million in Radial Health, a management services organization supporting Brain Medicine clinics, and $500,000 in Sound Minds Behavioral, a Mid-Atlantic outpatient mental health provider. The company describes both as minority stakes in provider networks.
Read more →Neuronetics promoted Cory Anderson from Chief Technology Officer to Executive Vice President and General Manager of Greenbrook, the large TMS and Spravato clinic network the company acquired in late 2024. The move took effect July 1, 2026.
Read more →Zeta Surgical received FDA clearance on July 10, 2026 for a robotic system that positions the TMS coil using AI and computer vision. The company says it aims to make stimulation placement more consistent in treatment-resistant depression.
Read more →BrainsWay presented the largest real-world dataset to date on Deep TMS for patients with comorbid PTSD and major depressive disorder. Among 462 patients, 83.5% achieved a PTSD response and depression symptoms improved substantially.
Read more →BrainsWay announced that favorable U.S. medical-policy coverage for its SWIFT accelerated Deep TMS protocol has grown to more than 57 million covered lives, after a new South Carolina policy added roughly 2 million members.
Read more →Wave Neuroscience received FDA 510(k) clearance for its MeRT (Magnetic EEG-guided Resonance Therapy) system to treat PTSD. It is the first FDA-cleared personalized, biomarker-guided neuromodulation technology for the condition.
Read more →BrainsWay presented the first prospective 12-month durability data for its SWIFT accelerated Deep TMS protocol at the Clinical TMS Society Annual Meeting. Preliminary analysis showed an over-80% remission rate one year after treatment.
Read more →The Clinical TMS Society held its 2026 Annual Meeting in Boston June 4–6, gathering TMS providers and researchers from around the world. The meeting served as the launchpad for major announcements from Neuronetics, BrainsWay, and MagVenture.
Read more →Neuronetics presented new real-world evidence from its TrakStar patient database at the 2026 Clinical TMS Society Annual Meeting, including NeuroStar effectiveness by age and sex, outcomes in adolescents aged 12–14, and a plenary on maintenance therapy.
Read more →MagVenture announced FDA clearance for accelerated TMS protocols to treat major depressive disorder in adults, allowing multiple sessions per day so a full course can be completed in days rather than the traditional four to six weeks.
Read more →Neuronetics announced a strategic collaboration with ANT Neuro to integrate image-guided neuronavigation into NeuroStar Advanced Therapy, offering ANT Neuro's visor2 system alongside NeuroStar for real-time coil targeting.
Read more →BrainsWay reported Q1 2026 revenue of $15.5 million, up about 35% year over year, and net income of $2.3 million. The company shipped 117 Deep TMS systems, up 44% year over year, and reiterated full-year guidance of $66–68 million.
Read more →MagVenture launched MagVenture Go, a compact and mobile TMS system built on the MagPro R20 platform that supports both rTMS and iTBS protocols, aimed at clinics needing flexible, movable treatment capacity.
Read more →Neuronetics reported Q1 2026 revenue of $34.5 million, up 8% year over year. U.S. clinic revenue rose 15% to $21.5 million, and the company shipped 34 NeuroStar systems in the U.S., a 10% increase over Q1 2025.
Read more →A multicenter randomized trial is testing the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol for postpartum depression across four U.S. sites, as described by Thalia Robakis, MD, PhD, of the Icahn School of Medicine at Mount Sinai.
Read more →BrainsWay publicized an expanding set of U.S. payer policies that allow trained psychiatric mental health nurse practitioners to order, supervise, and administer TMS therapy, led by Optum Behavioral Health's policy covering about 34.8 million commercial lives.
Read more →The Medical University of South Carolina says that in 2024 it became the first hospital system to offer Stanford Neuromodulation Therapy (SAINT), an accelerated form of TMS that treats depression in days rather than weeks, and cites roughly 80% remission by day five.
Read more →Optum, UnitedHealthcare, and United Behavioral Health updated their TMS clinical policy to let psychiatric mental health nurse practitioners order, supervise, and administer TMS therapy. Per Neuronetics, the change applies across 26 states and Washington, D.C.
Read more →University of Iowa researchers showed that noninvasive TMS can reliably modulate activity in the hippocampus — a deep brain structure long thought out of reach — but only when the stimulation site is personalized to each individual’s brain connectivity.
Read more →A narrative review in Brain Sciences of 34 studies (2015-2026) reports that TMS can reduce craving, daily cigarette consumption, and dependence, with several trials showing higher abstinence than sham, while calling for longer-follow-up trials.
Read more →A systematic review of three studies (62 women) describes TMS as potentially safe and effective for depression in pregnancy, while stressing the evidence is limited.
Read more →In March 2024 the FDA cleared NeuroStar as a first-line adjunctive treatment for major depressive disorder in adolescents aged 15 to 21.
Read more →In July 2022 the FDA cleared an expanded NeuroStar indication covering anxiety symptoms in adults with major depressive disorder ("anxious depression"), based on real-world data from Neuronetics' TrakStar platform.
Read more →Disclaimer: News items are for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare provider regarding treatment decisions.
Get weekly updates on new clinics, insurance coverage, and treatment advances.
With all this promising research, see if TMS therapy is right for you.
Cigna TMS Coverage 
UnitedHealthcare Coverage 
Kaiser Permanente Coverage Get instant access to our comprehensive guide
